| | | Overall | 2 transplants | 3 transplants | 4 transplants | | N = 377 | N = 340 (90.2%) | N = 34 (9.0%) | N = 3 (0.8%) |
| | Age at LT, years, median (IQR) | 52 (42–59) | 52 (44–59) | 43 (33–52) | 34 | | Male, number (%) | 225 (59.7) | 203 (59.7) | 19 (55.9) | 3 (100.0) | | Time from previous transplant, days, median (IQR) | 5 (10–809) | 47 (10–642) | 546 (43–1998) | 805 | | Unknown (n) = 76 (20.2%) | | Creatinine at LT, μmol/L, median (IQR) | 104 (82–183) | 103 (80–186) | 113 (97–179) | 117 | | Unknown (n) = 150 (39.8%) | | Serum bilirubin at LT, μmol/L, median (IQR) | 135.5 (52.8–409.5) | 135.5 (53.8–414.5) | 117.0 (32.0–370.0) | 277.0 | | Unknown (n) = 151 (40.1%) | | INR at LT, median (IQR) | 1.6 (1.3–2.3) | 1.6 (1.3–2.4) | 1.6 (1.2–1.8) | 1.4 | | Unknown (n) = 153 (40.6%) | | Blood type, number (%) | | A | 172 (45.6) | 153 (45.0) | 17 (50.0) | 2 (66.7) | | AB | 17 (4.5) | 15 (4.4) | 1 (2.9) | 1 (33.3) | | B | 58 (15.4) | 56 (16.5) | 2 (5.9) | 0 (0.0) | | O | 129 (34.2) | 116 (34.1) | 13 (38.2) | 0 (0.0) | | Unknown | 1 (0.3) | 0 (0.0) | 1 (2.9) | 0 (0.0) | | Liver diagnosis, number (%) | | AIH/PSC/PBC | 102 (27.1) | 91 (26.8) | 10 (29.4) | 1 (33.3) | | Alcoholic cirrhosis | 20 (5.3) | 20 (5.9) | 0 (0.0) | 0 (0.0) | | Hepatocellular carcinoma | 21 (5.6) | 18 (5.3) | 3 (8.8) | 0 (0.0) | | HBV | 21 (5.6) | 20 (5.9) | 1 (2.9) | 0 (0.0) | | HCV | 64 (17.0) | 61 (17.9) | 3 (8.8) | 0 (0.0) | | NASH | 10 (2.7) | 10 (2.9) | 0 (0.0) | 0 (0.0) | | Cryptogenic | 62 (16.4) | 51 (15.0) | 10 (29.4) | 1 (33.3) | | Other | 77 (20.4) | 69 (20.3) | 7 (20.6) | 1 (33.3) | | Previous organ failure cause, number (%) | | Primary nonfunction | 31 (8.2) | 29 (8.5) | 2 (5.9) | 0 (0.0) | | Portal vein thrombosis | 4 (1.1) | 4 (1.2) | 0 (0.0) | 0 (0.0) | | Hepatic vein thrombosis | 18 (4.8) | 16 (4.7) | 2 (5.9) | 0 (0.0) | | Hepatic artery thrombosis | 38 (10.1) | 36 (10.6) | 1 (2.9) | 1 (33.3) | | Acute rejection | 4 (1.1) | 4 (1.2) | 0 (0.0) | 0 (0.0) | | Chronic rejection | 11 (2.9) | 11 (3.2) | 0 (0.0) | 0 (0.0) | | Recurrence of original disease | 23 (6.1) | 21 (6.2) | 2 (5.9) | 0 (0.0) | | Other | 19 (5.0) | 18 (5.3) | 1 (2.9) | 0 (0.0) | | Unknown/uncertain | 229 (60.8) | 201 (59.1) | 26 (76.5) | 2 (66.7) | | BMI, kg/m2, median (IQR) | 24.9 (21.9–28.7) | 25.2 (22.2–29.0) | 23.9 (20.1–25.9) | 24.2 | | Unknown (n) = 27 (7.2%) | | MELD score at LT, median (IQR) | 24 (17–31) | 24 (17–32) | 23 (16–27) | 23 | | Unknown (n) = 154 (40.8%) | | Medical status, number (%) | | At home (1, 1T) | 74 (19.6) | 65 (19.1) | 8 (23.5) | 1 (33.3) | | Hospitalized (2) | 75 (19.9) | 65 (19.1) | 10 (29.4) | 0 (0.0) | | Hospitalized/ICU (3, 3F) | 44 (11.7) | 40 (11.8) | 3 (8.8) | 1 (33.3) | | ICU/ventilated (4, 4F) | 124 (32.9) | 117 (34.4) | 6 (17.7) | 1 (33.3) | | Unknown | 60 (16.0) | 53 (15.6) | 7 (20.6) | 0 (0.0) | | HCV positive, number (%) | 54 (14.3) | 53 (15.6) | 1 (2.9) | 0 (0.0) | | Unknown (n) = 139 (36.9%) | | CMV positive, number (%) | 182 (48.3) | 165 (48.5) | 17 (50.0) | 0 (0.0) | | Unknown (n) = 116 (30.8%) | | CIT, minutes, median (IQR) | 443 (327–572) | 443 (329–572) | 456 (289–590) | 474 | | Unknown (n) = 87 (23.1%) |
|
|
LT, liver transplantation; IQR, interquartile range; INR, international normalized ratio; AIH, autoimmune hepatitis; PSC, primary sclerosing cholangitis; PBC, primary biliary cholangitis; HBV, hepatitis B virus; HCV, hepatitis C virus; NASH, nonalcoholic steatohepatitis; BMI, body mass index; MELD, model for end-stage liver disease; ICU, intensive care unit; CMV, cytomegalovirus; CIT, cold ischemia time.
|
